October 3, 2018   Sweden
Intralymphatic immunotherapy with the diabetes vaccine Diamyd® explained
Video showing the novel antigen-specific immunotherapy Diamyd®, for the treatment of autoimmune diabetes.

Diamyd® is based on the protein GAD65, an activator of the immune system involved in the pathology of autoimmune diabetes. By preventing the autoimmune destruction of insulin producing cells, Diamyd® has the potential to significantly reduce the complications of type 1 diabetes and LADA. Diamyd® is in Phase II clinical development.
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.

Order GAD for preclinical research

GAD PRODUCTS